Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Interest in COVID-19 vaccine boosters on the upswing 

By Brian Buntz | April 28, 2021

Pfizer-BioNTech vaccine

Pfizer-BioNTech vaccine image courtesy of Wikipedia

Signs are growing that COVID-19 vaccine boosters will be required to fight waning immunity and SARS-CoV-2 variants.

An article recently published in NEJM describes how SARS-CoV-2 variants managed to cause breakthrough infection in two patients fully immunized with mRNA vaccines. The 15 authors support “efforts to advance a new vaccine booster (as well as a pan-coronavirus vaccine) to provide increased protection against variants.”

While such breakthrough infections remain rare, they may grow more common as immunity from vaccines wanes. Data suggests that mRNA vaccines offer strong protection for at least six months. It is likely that immunity will wane sometime in another six to 12 months.

Pfizer CEO Dr. Albert Bourla has said that boosters of the vaccine will likely be necessary, as did BioNTech cofounders Dr. Ugur Sahin and Dr. Özlem Türeci.

The U.K. has already purchased 60 million additional doses of vaccine from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) for use as boosters later this year.

And Chinese vaccine makers Sinovac and Sinopharm are exploring the potential of a booster vaccine and the possibility of sequential immunization. That is, using multiple vaccines to optimize efficacy.

The White House has said it is preparing for the use of boosters between nine to 12 months after full vaccination.

Data aren’t yet available, however, to make a case for when boosters should be administered. The duration of immunity may vary according to vaccine type. Adenovirus-vector vaccines themselves are potentially ill-suited for repeated use as boosters, given their potential to cause immunity to the vector.

Another factor is the continued spread of COVID-19 infections in many parts of the world, which could drive further viral mutations that threaten vaccinated immunity over time. Such mutations would underscore the need for boosters customized to emerging variants.

Companies like Pfizer and Moderna are also testing the potential of their original COVID-19 vaccines for use as boosters. Pfizer is testing administering a third dose of its vaccine six to 12 months after recipients received the second dose.

Both companies are also making a booster optimized against the B.1.351 variant, commonly referred to as the “South African variant.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Pfizer logo
Pfizer and BioNTech seek EMA authorization for COVID-19 vaccination in young children
Pfizer logo
FDA allows pharmacists to prescribe Paxlovid 
vaccine
Will COVID-19 vaccines be updated by fall? 
COVID-19 vaccine
Young children in U.S. now eligible for COVID-19 vaccination

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards